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OBJECTIVES We investigated the relationship between the urinary levels of biopyrrins and the severity of
heart failure (HF).
BACKGROUND Oxidative stress is evident in heart disease and contributes to the development of ventricular
dysfunction in patients with HF. Biopyrrins, oxidative metabolites of bilirubin, have been
discovered as potential markers of oxidative stress.
METHODS We measured the levels of urinary biopyrrins and plasma B-type natriuretic peptide (BNP) in
94 patients with HF (59 men; mean age 65 years) and 47 control subjects (30 men; mean age
65 years). Urine and blood samples were taken after admission in all subjects. Further urine
samples were obtained from 40 patients after treatment of HF.
RESULTS The urinary biopyrrins/creatinine levels (mol/g creatinine) were the highest in patients in
New York Heart Association (NYHA) class III/IV (n  26; 17.05 [range 7.85 to 42.91]).
The urinary biopyrrins/creatinine levels in patients in NYHA class I (n 35; 3.46 [range 2.60
to 5.42]) or II (n  33; 5.39 [range 3.37 to 9.36]) were significantly higher than those in
controls (2.38 [range 1.57 to 3.15]). There were significant differences in urinary biopyrrins/
creatinine levels among each group. The treatment of HF significantly decreased both urinary
biopyrrins/creatinine levels (from 7.43 [range 3.84 to 17.05] to 3.07 [range 2.21 to 5.71]) and
NYHA class (from 2.5  0.1 to 1.7  0.1). Log biopyrrins/creatinine levels were positively
correlated with log BNP levels (r  0.650, p  0.001).
CONCLUSIONS These results indicate that urinary biopyrrins levels are increased in patients with HF and are
elevated in proportion to its severity. (J Am Coll Cardiol 2004;43:1880–5) © 2004 by the
American College of Cardiology Foundationt
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wongestive heart failure (HF) is a major cause of morbidity
nd mortality (1). Both acute and chronic HF has been
eported to be associated with increased oxidative stress and
educed antioxidant reserve (2). Indeed, reactive oxygen
pecies (ROS) have been reported to be involved in both the
enesis and progression of HF (3–6).
Bilirubin may be harmful in vivo, as marked elevation of
erum levels can result in the neuronal injury associated with
ernicterus. Recently, however, the antioxidative action of
ilirubin has been clarified in vitro, and bilirubin is now
onsidered to be an important scavenger of ROS in vivo
7–9). Oxidative metabolites of bilirubin have been identi-
ed in human urine and plasma using an antibilirubin
onoclonal antibody (10). These metabolites were desig-
ated as biopyrrins and are considered to represent potential
arkers of oxidative stress (11). Recently, we have reported
n the relationship between the prognosis of acute myocar-
ial infarction and oxidative stress using urinary biopyrrins
evels (12).
From the *Department of Cardiovascular Medicine, Kumamoto University School
f Medicine, Kumamoto; †Division of Cardiology, Fukuoka Tokushukai Hospital,
ukuoka; and ‡Shino-Test Corporation, Tokyo, Japan. This study was supported in
art by a research grant for cardiovascular disease (14C-4) from the Ministry of
ealth and Welfare, as well as by a grant-in-aid for scientific research (B15390248
nd 14770318) from the Ministry of Education, Science and Culture, Japan. Dr.
ichard Rodeheffer acted as Guest Editor for this article.
Manuscript received August 25, 2003; revised manuscript received December 24,c003, accepted January 8, 2004.We and others have shown that B-type natriuretic pep-
ide (BNP) is predominantly secreted and released from the
entricles in proportion to the severity of left ventricular
ysfunction in patients with HF, and there is increasing
vidence that BNP is a sensitive marker of the severity of
F (13–16).
We postulated that urinary biopyrrins may be used as a
arker of oxidative stress in vivo and may be a useful marker
f the severity of HF. Therefore, in the present study, we
xamined the relationship between urinary biopyrrins levels,
he severity of HF by New York Heart Association
NYHA) functional class, and the plasma levels of BNP.
ETHODS
tudy population. The study population consisted of 94
onsecutive patients with heart disease (59 men and 35
omen; mean age 65  1 year). The diagnosis of heart
isease was based on the patient’s clinical history, physical
xamination, electrocardiogram (ECG), chest X-ray, echo-
ardiogram, left ventriculogram, and coronary angiogram.
atients in NYHA functional class I had cardiac disease that
id not limit physical activity, such that ordinary physical
ctivity did not cause undue fatigue, palpitation, dyspnea, or
nginal pain. The remaining patients with heart disease
ere symptomatic for HF. Patients in NYHA functionallass III/IV had significant clinical findings (e.g., edema, S3,
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May 19, 2004:1880–5 Oxidative Stress in HFulmonary congestion). The cause of heart disease was
diopathic dilated cardiomyopathy in 18 patients, hypertro-
hic cardiomyopathy in 9, old myocardial infarction in 37,
ypertensive heart disease in 12, valvular heart disease in 16,
nd congenital heart disease in 2. Patients with malignant
isease, severe lung disease, severe renal failure, and severe
iver dysfunction were excluded. The NYHA functional
lassification was evaluated at the time of admission. Left
entricular ejection fraction (LVEF) was also measured by
impson’s rule, using echocardiography.
We also included 47 controls (30 men and 17 women;
ean age 65  2 years), who were age-matched with the
atients with heart disease. All of the controls underwent
iagnostic cardiac catheterization because they had a history
f chest pain with multiple risk factors or an ECG abnor-
ality. However, their coronary angiograms revealed no
vidence of coronary stenosis or coronary spasm after
ntracoronary injection of acetylcholine. Written, informed
onsent was obtained from all subjects before the study. The
tudy was in agreement with the guidelines approved by the
thics Committee at our institution.
rinary biopyrrins assays. In all subjects, urine samples for
iopyrrins were taken immediately after admission. Of 59
atients with HF (NYHA classes II and III/IV), 40 patients
nderwent repeat urinary sampling and a re-evaluation of
he NYHA class at the time of discharge. The remaining 19
atients required percutaneous coronary interventions or
peration or developed complications such as pneumonia,
erebral infarction, and deterioration of renal function.
ccording to clinical indications, all 40 patients were
reated with varying combinations of angiotensin-
onverting enzyme inhibitors or angiotensin II type 1
eceptor blockers (78%), diuretics (80%), beta-blockers
40%), digitalis (20%), and vasodilators (50%). All urine
amples were immediately stored at 80°C and protected
rom light until analyzed.
Urinary biopyrrins were measured in duplicate, using a
iopyrrins enzyme immuno assay kit based on monoclonal
ntibody (Shino-test Co., Tokyo, Japan) (10,12). The
esults were then corrected to the urinary concentration of
reatinine, which was determined with the Accuras Auto
RE (Shino-test Co.). The urinary biopyrrins/creatinine
atio was used in subsequent analyses (12). The intra-assay
oefficient of variation for the same samples (n  10) was
.4% in triplicate, whereas the interassay coefficient of
ariation for the same samples (n  10) was 8.5% in three
xperiments.
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
HF  heart failure
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
ROS  reactive oxygen speciesllasma BNP assays. To determine plasma BNP, blood
amples from an antecubital vein were obtained immediately
fter admission in all subjects. Blood samples for plasma
NP and urine samples for biopyrrins were obtained on the
ame day. The plasma BNP concentration was measured
ith a specific radioimmunoassay for human BNP, as
reviously described (14).
tatistical analysis. All results without plasma levels of
NP and urinary levels of biopyrrins/creatinine are ex-
ressed as the mean value  SEM. Comparisons of con-
inuous data between multiple groups were determined by
ne-way analysis of variance, followed by the Scheffe´ F test.
he frequency data were compared by the chi-square test.
lasma levels of BNP and urinary levels of biopyrrins/
reatinine were not distributed normally. Thus, the results
f plasma BNP and urinary biopyrrins/creatinine levels are
xpressed as the median value (25th to 75th percentile
ange), and nonparametric analysis was used. The Mann-
hitney U test was used to evaluate differences in the levels
f biopyrrins/creatinine between the two groups. Compar-
sons of plasma BNP and urinary biopyrrins/creatinine
evels among multiple groups were determined by both the
ruskal-Wallis and Mann-Whitney U tests. Log BNP and
og biopyrrins/creatinine levels were used for linear regres-
ion analysis, which was used to determine the correlation
etween the two variables. The changes in NYHA func-
ional class before and after treatment were compared by the
aired t test. Change in the levels of biopyrrins/creatinine
ere compared by the Wilcoxon signed-rank test. A p value
0.05 was considered significant.
ESULTS
he 94 patients with heart disease were classified into three
lasses according to NYHA functional classification: 35
atients were in NYHA class I, 33 in class II, and 26 in class
II/IV.
The clinical characteristics of the study subjects are
able 1. Patient Characteristics
Control Group
(n  47)
Heart Failure
Group (n  94)
ge (yrs) 65  2 65  1
en/women (n) 30/17 59/35
ypertension 22 (47%) 46 (49%)
moking 9 (19%) 23 (24%)
iabetes mellitus 7 (15%) 18 (19%)
besity (BMI 25 kg/m2) 12 (26%) 25 (27%)
otal cholesterol (mg/dl) 192  6 187  3
DL cholesterol (mg/dl) 51  2 53  2
DL cholesterol (mg/dl) 121  5 115  3
riglycerides (mg/dl) 133  10 116  8
rinary biopyrrins/creatinine
(mol/g creatinine)
2.38 (1.57–3.15) 5.91 (3.33–10.45)*
p  0.001 vs. controls. Data are expressed as the mean value  SEM or number (%)
f subjects. Results of urinary biopyrrins/creatinine levels are expressed as the median
alue (25th to 75th percentile range).
BMI  body mass index; HDL  high-density lipoprotein; LDL  low-density
ipoprotein.
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Oxidative Stress in HF May 19, 2004:1880–5hown in Table 1. Heart rate was the highest in patients in
YHA class III/IV (Table 2). The LVEF was significantly
ower in patients in NYHA classes II and III/IV than in
ontrols (class II vs. controls: p  0.001; class III/IV vs.
ontrols: p  0.001). The LVEF was reduced in patients in
YHA class III/IV, compared with patients in class I or II
class III/IV vs. class I: p  0.001; class III/IV vs. class II:
 0.05). There were no differences in LVEF between the
ontrols and patients in NYHA class I. The BNP levels
ere the highest in patients in NYHA class III/IV. The
lasma levels of BNP were significantly higher in patients in
YHA class I or II than in controls (p 0.001). Moreover,
ach group had significant differences in plasma levels of
NP.
rinary levels of biopyrrins/creatinine. The urinary levels
f biopyrrins/creatinine (mol/g creatinine) were signifi-
antly increased in patients with HF compared with con-
rols (p 0.001) (Table 1). The urinary levels of biopyrrins/
reatinine were the highest in patients in NYHA class
II/IV (17.05 [range 7.85 to 42.91]) (Fig. 1). The urinary
evels of biopyrrins/creatinine in patients in NYHA class I
3.46 [range 2.60 to 5.42]) or II (5.39 [range 3.37 to 9.36])
ere higher than those in controls (2.38 [range 1.57 to
able 2. New York Heart Association Functional Classes and He
Control Group
(n  47)
Clas
(n 
R (beats/min) 65  2*† 70 
P (mm Hg) 132  2/78  1 128  4/
VEF (%) 61.7  1.4*‡ 54.8 
NP (pg/ml) 24.9*‡§ (13.3–38.3) 80.2*‡ (29
p  0.001 vs. class III/IV. †p  0.05 vs. class II. ‡p  0.001 vs. class II. §p  0.001
f plasma BNP levels are expressed as the median value (25th to 75th percentile ran
BNP  B-type natriuretic peptide; BP  blood pressure; HR  heart rate; LVE
igure 1. Comparison of urinary levels of biopyrrins/creatinine among the
atients in New York Heart Association (NYHA) functional classes I, II,
nd III/IV and controls. The horizontal line in the box represents the
edian value; the boxed area is the interquartile range; and the whiskersre the 10% to 90% range. B.15]) (Fig. 1). Furthermore, there were significant differ-
nces in urinary levels of biopyrrins/creatinine among the
roups (Fig. 1). Log biopyrrins/creatinine levels were sig-
ificantly and positively correlated with log BNP levels, as
hown in Figure 2 (r  0.650, p  0.001).
Log biopyrrins/creatinine levels were significantly and
ositively correlated with pulmonary artery wedge pressure
r  0.327, p  0.001) and mean pulmonary artery pressure
r  0.389, p  0.001). Log biopyrrins/creatinine levels
ere significantly and negatively correlated with the cardiac
ndex (r  0.338, p  0.001). However, there was no
orrelation between log biopyrrins/creatinine levels and
ight atrial pressure. Furthermore, log biopyrrins/creatinine
evels were significantly and negatively correlated with
VEF (r  0.415, p  0.001). The treatment of HF
ecreased both the NYHA class (from 2.5  0.1 to 1.7 
.1, p  0.001) and the biopyrrins/creatinine levels (from
.43 [range 3.84 to 17.05] to 3.07 [range 2.21 to 5.71], p 
.001), as shown in Figure 3.
ISCUSSION
o the best of our knowledge, this is the first clinical report
o analyze the urinary levels of biopyrrins in patients with
F. The present study provides clinical evidence that the
rinary levels of biopyrrins/creatinine are changed in asso-
iation with both NYHA functional class and plasma levels
f BNP.
Recently, increases in plasma biochemical markers of
xidative stress have been reported in patients with HF
ynamic Variables
Class II
(n  33)
Class III/IV
(n  26)
77  4* 98  4
2 130  6/72  3 128  7/81  5
46.7  2.7¶ 36.3  3.6
3.0) 232.0* (109.1–294.0) 404.5 (280.0–686.0)
s I. ¶p  0.05 vs. class III/IV. Data are expressed as the mean value  SEM. Results
left ventricular ejection fraction.
igure 2. Correlation between log biopyrrins/creatinine levels and logmod
s I
35)
2*
75 
2.7*
.3–15
vs. clas
ge).-type natriuretic peptide (BNP) levels.
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May 19, 2004:1880–5 Oxidative Stress in HF17,18). There is a definitive correlation between oxidative
tress and ventricular dysfunction (2,4). Furthermore, ven-
ricular remodeling and progressive dilation leading to
nd-stage HF may be mediated by oxygen-derived free
adicals (2,4). Therefore, it is likely that ROS are involved
n not only the pathogenesis but also the active progression
f HF (3–6). In an attempt to prevent the production of
xidants, as well as to ameliorate and repair oxidative tissue
amage, detoxification systems are present in vivo and
omprise both enzymatic and nonenzymatic antioxidant
ompounds. Stocker et al. (7,19) have demonstrated a
eneficial role for bilirubin by demonstrating the powerful
ntioxidant activity of bilirubin in vivo. The antioxidant
ffect of bilirubin exceeded that of alpha-tocopherol under
% oxygen, which is near physiologic intracellular oxygen
evels (20). In the present study, we measured biopyrrins,
he oxidative metabolites of bilirubin, in patients with HF.
e provide clinical evidence that the urinary levels of
iopyrrins/creatinine are significantly increased in patients
ith HF compared with controls. These data are compatible
ith the finding that HF is associated with increased
xidative stress, the extent of which has a close relation to
igure 3. (A) Bar graphs comparing New York Heart Association
NYHA) functional classes before and after the active treatment of heart
ailure (mean SEM). (B) Box plots of urinary biopyrrins/creatinine levels
efore and after the active treatment of heart failure. The horizontal line
n the box represents the median value; the boxed area is the interquartile
ange; and the whiskers are the 10% to 90% range.he degree of HF (17,21,22). Furthermore, the present Btudy demonstrates that the urinary levels of biopyrrins in
atients with HF were elevated in proportion to its severity
nd subsequently decreased after the active treatment of
F. Thus, we postulate that the increased urinary biopy-
rins levels may indirectly reflect the excessive oxidative
tress caused by ROS associated with uncontrolled HF, and
hat there is an apparent normalization of these indexes of
xidative stress after treatment of HF.
The etiology of increased oxidative stress is still unclear.
eart failure is a clinical syndrome characterized by long-
erm, persistent activation of the sympathetic nervous sys-
em and renin-angiotensin-aldosterone system (23,24). The
omeostatic mechanisms seem activated in response to a
erceived reduction in circulating blood volume in patients
ith HF. The resultant effect is the development of a
icious cycle characterized by excessive neurohormonal
timulation that is responsible for not only the persistent
xpression of adverse hemodynamic abnormalities but also
yocardial and vascular remodeling, a hallmark of progres-
ive HF (23). For example, norepinephrine is elevated in
F, because sympathetic activation is an early mechanism
hat maintains cardiac output in HF (23,25). However,
orepinephrine produces free radicals and promotes cardi-
myocyte apoptosis (25–27). The loss of cardiomyocytes by
poptosis has emerged as an important factor contributing
o ventricular remodeling (25). The cardiomyocyte apopto-
is and generation of ROS may be triggered by mechanical
orce, cytokines (e.g., angiotensin II), and neurotransmitters
e.g., norepinephrine) (25). Moreover, many studies have
emonstrated that oxidative stress may activate the apopto-
ic cell death of cardiomyocytes (25,28). Thus, oxidative
tress contributes to ventricular remodeling, and the mag-
itude of oxidative stress is related to the severity of HF.
On the other hand, plasma levels of BNP reflect the
egree of left ventricular remodeling, damage, or dysfunc-
ion, and BNP is an important prognostic predictor for
atients with HF (29–32). In the present study, to examine
hether the urinary biopyrrins levels in patients with HF
ight be related to the severity of HF, we also examined the
lasma levels of BNP in addition to NYHA functional class.
he present study showed that log biopyrrins/creatinine
evels are closely and positively correlated to log BNP levels.
atriuretic peptides are released in response to increased
ntracardiac volume or pressure (33). It has been shown that
verstretching of the myocardium leads to enhanced gener-
tion of ROS (34). Moreover, angiotensin II may be
onsidered a prime stimulus of oxidative stress and increases
eneration of ROS within cardiomyocytes (35). Production
f ROS may cause mitochondrial DNA damage and de-
rease activity, thereby contributing to the increase in
xidative stress. Furthermore, angiotensin II also worsens
F. In rats, infusion of angiotensin II induced expression of
arious genes, including BNP (36). Suo et al. (37) demon-
trated that left ventricular BNP messenger ribonucleic acid
nd immunoreactive BNP levels are distinctly regulated by
NP promoter activity in an angiotensin II–induced model
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Oxidative Stress in HF May 19, 2004:1880–5f experimental hypertension in vivo. These pathophysio-
ogic mechanisms might account for the significant corre-
ation between the urinary levels of biopyrrins and plasma
evels of BNP in patients with HF. In fact, both the NYHA
unctional class and the biopyrrins/creatinine levels de-
reased after treatment of HF. In congestive HF, myocar-
ial contractility is impaired by either a loss of muscle or by
ressure or volume overload, which causes myocardial isch-
mia and generation of ROS (38,39). Based on these results,
e postulated that urinary biopyrrins levels, a new oxidative
tress marker, related to the severity of HF and had a close
orrelation with BNP.
In the present study, the ejection fractions from each of
he categories of HF patients are high. In previous study, it
as demonstrated that plasma BNP levels increase in
atients with diastolic dysfunction (40). Because we used
NP as one of the parameters in HF severity, the causes of
F included not only systolic dysfunction but also diastolic
ysfunction. Moreover, the patients with active ischemia
ausing intermittent cardiac congestion comprised 6% of the
F group. These may be reasons that the ejection fractions
rom each of the categories of HF patients are high.
tudy limitations. In the present study, antioxidants (e.g.,
itamin E, carvedilol) did not have any effects on the
iopyrrins levels. Unfortunately, the observation period may
e too short, and the antioxidant therapy group may be too
mall. In addition, we excluded both patients with renal
ailure and those with liver dysfunction. We need further
tudies to clarify the effects of antioxidants and liver and
enal diseases on biopyrrins levels.
We do not have detailed data on the half-life of biopy-
rins. We reported dynamic changes of biopyrrins within a
ew hours in patients with acute myocardial infarction (12).
ther investigators also showed dynamic changes of biopy-
rins within 24 h after acute coronary artery occlusion in
atients with coronary spasm (41). These data suggest that
he concentration of biopyrrins might change within a short
ime in humans.
onclusions. The urinary levels of biopyrrins/creatinine
re closely related to both NYHA functional class and
lasma levels of BNP. Because the measurement of urinary
iopyrrins is noninvasive, urinary biopyrrins may be clini-
ally useful markers of oxidative stress. The urinary biopy-
rins/creatinine levels may imply the HF severity.
eprint requests and correspondence: Dr. Hiroaki Kawano,
epartment of Cardiovascular Medicine, Kumamoto University
chool of Medicine, 1-1-1 Honjo, Kumamoto City 860-8556,
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